Monoclonal antibodies against amyloid beta protein and uses thereof

Abstract

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

1 - 56 . (canceled) 
     
     
         57 . A method of treating or preventing Alzheimer's Disease in a patient in need of said treatment or prevention, the method comprising the steps of: administering to a patient an isolated antibody in an amount sufficient to effect said treatment or prevention in the patient, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:8;   ii) a CDR 2 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:9;   iii) a CDR 3 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:10;   iv) a CDR 1 of the heavy chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:5;   v) a CDR 2 of the heavy chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:6; and   vi) a CDR 3 of the heavy chain variable region of the monoclonal antibody comprising theamino acid sequence of SEQ ID NO: 7.   
     
     
         58 . A method of treating or preventing Alzheimer's Disease in a patient in need of said treatment or prevention, the method comprising the steps of: administering to a patient an isolated antibody in an amount sufficient to effect said treatment or prevention in the patient, wherein the antibody is a monoclonal antibody comprising the complementarity determining regions of SEQ ID NO:3 and SEQ ID NO:4, wherein said antibody is murine, human or humanized. 
     
     
         59 . A method of treating or preventing Alzheimer's Disease in a patient in need of said treatment or prevention, the method comprising the steps of: administering to a patient an isolated antibody in an amount sufficient to effect said treatment or prevention in the patient, wherein the antibody is a monoclonal antibody which specifically binds to forms of amyloid beta, wherein:
 i) the light chain variable region of the monoclonal antibody comprises the amino acid sequence of RSSQSLVYSNGDTYLH (SEQ ID NO: 8); the amino acid sequence of KVSNRFS (SEQ ID NO: 9); and the amino acid sequence of SQSTHVPWT (SEQ ID NO: 10); and   ii) the heavy chain variable region of the monoclonal antibody comprises the amino acid sequence of GFTFSSYGMS (SEQ ID NO: 24); the amino acid sequence of SINSNGGSTYYPDSVKG (SEQ ID NO: 6); and the amino acid sequence of GDY (SEQ ID NO: 25).   
     
     
         60 . A method of treating or preventing Alzheimer's Disease in a patient in need of said treatment or prevention, the method comprising the steps of: administering to a patient an isolated antibody in an amount sufficient to effect said treatment or prevention in the patient, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:8;   ii) a CDR 2 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:9; and   iii) a CDR 3 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:10; and   iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3.   
     
     
         61 . A method of treating or preventing Alzheimer's Disease in a patient in need of said treatment or prevention, the method comprising the steps of: administering to a patient an isolated antibody in an amount sufficient to effect said treatment or prevention in the patient, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5;   ii) a CDR 2 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6;   iii) a CDR 3 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7; and   iv) a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.   
     
     
         62 . The method of  claim 57 ,  58 ,  59 ,  60  or  61  wherein said isolated antibody is administered via a route selected from the group consisting of intramuscular administration, intravenous administration and subcutaneous administration. 
     
     
         63 . A method of preventing or treating Alzheimer's Disease in a patient in need of said prevention or treatment comprising the step of administering a vaccine to a patient in an amount sufficient to effect said prevention or treatment, wherein the vaccine comprises an antibody, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:8;   ii) a CDR 2 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:9;   iii) a CDR 3 of the light chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:10;   iv) a CDR 1 of the heavy chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:5;   v) a CDR 2 of the heavy chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO:6; and   vi) a CDR 3 of the heavy chain variable region of the monoclonal antibody comprising the amino acid sequence of SEQ ID NO: 7.   
     
     
         64 . A method of preventing or treating Alzheimer's Disease in a patient in need of said prevention or treatment comprising the step of administering a vaccine to a patient in an amount sufficient to effect said prevention or treatment, wherein the vaccine comprises an antibody, wherein the antibody is a monoclonal antibody comprising the complementarity determining regions of SEQ ID NO:3 and SEQ ID NO:4, wherein said antibody is murine, human or humanized. 
     
     
         65 . A method of preventing or treating Alzheimer's Disease in a patient in need of said prevention or treatment comprising the step of administering a vaccine to a patient in an amount sufficient to effect said prevention or treatment, wherein the vaccine comprises an antibody, wherein the antibody is a monoclonal antibody which specifically binds to forms of amyloid beta, wherein:
 i) the light chain variable region of the monoclonal antibody comprises the amino acid sequence of RSSQSLVYSNGDTYLH (SEQ ID NO: 8); the amino acid sequence of KVSNRFS (SEQ ID NO: 9); and the amino acid sequence of SQSTHVPWT (SEQ ID NO: 10); and   ii) the heavy chain variable region of the monoclonal antibody comprises the amino acid sequence of GFTFSSYGMS (SEQ ID NO: 24); the amino acid sequence of SINSNGGSTYYPDSVKG (SEQ ID NO: 6); and the amino acid sequence of GDY (SEQ ID NO: 25).   
     
     
         66 . A method of preventing or treating Alzheimer's Disease in a patient in need of said prevention or treatment comprising the step of administering a vaccine to a patient in an amount sufficient to effect said prevention or treatment, wherein the vaccine comprises an antibody, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:8;   ii) a CDR 2 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:9; and   iii) a CDR 3 of the light chain variable region comprising the amino acid sequence of SEQ ID NO:10; and   iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3.   
     
     
         67 . A method of preventing or treating Alzheimer's Disease in a patient in need of said prevention or treatment comprising the step of administering a vaccine to a patient in an amount sufficient to effect said prevention or treatment, wherein the vaccine comprises an antibody, wherein the antibody is a monoclonal antibody comprising:
 i) a CDR 1 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5;   ii) a CDR 2 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6;   iii) a CDR 3 of the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7; and   iv) a light chain variable region comprising the amino acid sequence of SEQ ID NO:4.